{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
US Previously Marketed
Source:
CHOLOVUE by BRACCO
(1981)
Source URL:
First approved in 1981
Source:
CHOLOVUE by BRACCO
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Iodoxamic acid (previously sold under the brand name Cholovue) is an organoiodine compound that was used as a contrast medium. It is intravenous cholecystocholangiographic
agent. It features both a high iodine content as well as several hydrophilic groups.
Status:
First approved in 1954
Class (Stereo):
CHEMICAL (EPIMERIC)
Conditions:
Tocamphyl is a choleretic agent derived from a root extract of Curcuma longa, L. The drug was marketed in Japan, however, it is no longer available.
Status:
Possibly Marketed Outside US
First approved in 2014
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Phenylpropanol is used as a heat transfer medium, in perfumery, and as a choleretic; used as a flavoring agent. It is used clinically as choleretic drug.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Metochalcone is a chalcone. It was isolated from heartwood of Pterocarpus marsupium. It has been approved for clinical use as choleretic and diuretic agent. It was made from 2,4-dihydroxybenzaldehyde (beta-resorcaldehide).
Status:
Possibly Marketed Outside US
Source:
NCT02173964: Phase 4 Interventional Completed Cancer
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Pinaverium, known under the brand name DICETEL, is a spasmolytic agent used for functional gastrointestinal disorders. It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function. It is shown to relieve GI spasm and pain, transit disturbances and other symptoms related to motility disorders and may be considered as effective first-lline therapy for patients with irritable bowel syndrome (IBS). Pinaverium is also used to help relieve symptoms caused by certain disorders of the gallbladder associated with secretion of bile. Pinaverium bromide is the common ingredient in formulations, mostly as oral tablets. Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada. DICETEL® (pinaverium bromide) is a calcium antagonist which inhibits the calcium influx by
blocking the voltage-dependent calcium channel at the smooth muscle cell level. It possesses a high degree of selectivity for the intestinal smooth muscle.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Tiquizium is an antispasmodic agent used to treat disorders of the
gastrointestinal, biliary, and urinary systems. Tiquizium is available commercially in Japan for the treatment of gastrointestinal disease. Tiquizium shows anti-muscarinic action to improve convulsion and hypermobility of intestinal smooth muscle.
It is usually used to treat convulsion and hypermobility in gastritis, gastric ulcer, duodenal ulcer, enteritis, irritable bowel syndrome, gallbladder disease, biliary tract disease and urolithiasis.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Iotroxic acid (INN), also known as meglumine iotroxate (BAN) (Biliscopin) for infusion is indicated for radiological examination of the hepatic and biliary ducts and gallbladder when examination by oral technique is unsuccessful or inappropriate. Following intravenous administration Biliscopin is rapidly excreted, mainly by the liver into the bile. Visualisation of the hepatic and common bile ducts and the gallbladder can, therefore, be achieved. Visualisation of the biliary ducts is usually possible 30-60 minutes after completion of administration. In vitro meglumine iotroxate binds to plasma proteins to the extent of 60-90% depending on concentration. In animals it crosses the placental barrier. This agent is the single intravenous cholangiographic agent, which is currently available in Australia.
Status:
US Previously Marketed
Source:
CHOLOVUE by BRACCO
(1981)
Source URL:
First approved in 1981
Source:
CHOLOVUE by BRACCO
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Iodoxamic acid (previously sold under the brand name Cholovue) is an organoiodine compound that was used as a contrast medium. It is intravenous cholecystocholangiographic
agent. It features both a high iodine content as well as several hydrophilic groups.
Status:
Possibly Marketed Outside US
Source:
NCT02173964: Phase 4 Interventional Completed Cancer
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Pinaverium, known under the brand name DICETEL, is a spasmolytic agent used for functional gastrointestinal disorders. It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function. It is shown to relieve GI spasm and pain, transit disturbances and other symptoms related to motility disorders and may be considered as effective first-lline therapy for patients with irritable bowel syndrome (IBS). Pinaverium is also used to help relieve symptoms caused by certain disorders of the gallbladder associated with secretion of bile. Pinaverium bromide is the common ingredient in formulations, mostly as oral tablets. Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada. DICETEL® (pinaverium bromide) is a calcium antagonist which inhibits the calcium influx by
blocking the voltage-dependent calcium channel at the smooth muscle cell level. It possesses a high degree of selectivity for the intestinal smooth muscle.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Iotroxic acid (INN), also known as meglumine iotroxate (BAN) (Biliscopin) for infusion is indicated for radiological examination of the hepatic and biliary ducts and gallbladder when examination by oral technique is unsuccessful or inappropriate. Following intravenous administration Biliscopin is rapidly excreted, mainly by the liver into the bile. Visualisation of the hepatic and common bile ducts and the gallbladder can, therefore, be achieved. Visualisation of the biliary ducts is usually possible 30-60 minutes after completion of administration. In vitro meglumine iotroxate binds to plasma proteins to the extent of 60-90% depending on concentration. In animals it crosses the placental barrier. This agent is the single intravenous cholangiographic agent, which is currently available in Australia.